Toggle light / dark theme

NASA scientists and their colleagues are now proposing corporate financing for a human mission to Mars. This raises the prospect that a spaceship named the Microsoft Explorer or the Google Search Engine could one day go down in history as the first spaceship to bring humans to the Red Planet.

The proposal suggests that companies could drum up $160 billion for a human mission to Mars and a colony there, rather than having governments fund such a mission with tax dollars.

Joel Levine, a senior research scientist at NASA Langley Research Center, was quoted in a release in the Journal of Cosmology by Dr. Rhawn Joseph. The plan covers “every aspect of a journey to the Red Planet — the design of the spacecrafts, medical health and psychological issues, the establishment of a Mars base, colonization, and a revolutionary business proposal to overcome the major budgetary obstacles which have prevented the U.S. from sending astronauts to Mars,” said Levine.

Severe allergy-like reactions in at least eight people who received the COVID-19 vaccine produced by Pfizer and BioNTech (and Moderna now) over the past 2 weeks may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccine’s main ingredient, scientists say. A similar mRNA vaccine developed by Moderna, which was authorized for emergency use in the United States on Friday, also contains the compound, polyethylene glycol (PEG) PEG has never been used before in an approved vaccine, but it is found in many drugs that have occasionally triggered anaphylaxis—a potentially life-threatening reaction that can cause rashes, a plummeting blood pressure, shortness of breath, and a fast heartbeat. Some allergists and immunologists believe a small number of people previously exposed to PEG may have high levels of antibodies against PEG, putting them at risk of an anaphylactic reaction to the vaccine.


Life-threatening responses seen in at least eight people could be linked to polyethylene glycol, known to trigger reactions to some drugs.

Federal officials are disappointed to find that the monoclonal antibody drugs they’ve shipped across the country aren’t being used rapidly.

These drugs are designed to prevent people recently diagnosed with COVID-19 from ending up in the hospital. But hospitals are finding it cumbersome to use these medicines, which must be given by IV infusion. And some patients and doctors are lukewarm about drugs that have an uncertain benefit.

Doctors hope that as word gets out, more people will end up trying these drugs. They are provided to health systems free by the federal government, but it costs money to administer the medication. At first, Medicare set a price that would require many patients to pay a $60 copay, but the Centers for Medicare and Medicaid Services later found a way to waive that fee.


Monoclonal antibodies to prevent severe COVID-19 aren’t being used as widely as expected. Medical staff shortages and patient transportation problems are two of the reasons.

Summary: Artificial intelligence technology redesigned a bacterial protein that helps researchers track serotonin in the brain in real-time.

Source: NIH

Serotonin is a neurochemical that plays a critical role in the way the brain controls our thoughts and feelings. For example, many antidepressants are designed to alter serotonin signals sent between neurons.

In an article in Cell, National Institutes of Health-funded researchers described how they used advanced genetic engineering techniques to transform a bacterial protein into a new research tool that may help monitor serotonin transmission with greater fidelity than current methods. Preclinical experiments, primarily in mice, showed that the sensor could detect subtle, real-time changes in brain serotonin levels during sleep, fear, and social interactions, as well as test the effectiveness of new psychoactive drugs.

“Once they are ingested, up to 90% of the plastic fragments that reach the intestine are excreted. However, one part is fragmented into nanoplastics which are capable, due to their small size and molecular properties, to penetrate the cells and cause harmful effects. The study establishes that alterations in food absorption have been described, as well as inflammatory reactions in the intestinal walls, changes in the composition and functioning of the gut microbiome, effects on the body’s metabolism and ability to produce, and lastly, alterations in immune responses. The article alerts about the possibility of a long-term exposure to plastic, accumulated throughout generations, could give way to unpredictable changes even in the very genome, as has been observed in some animal models.”


We live in a world invaded by plastic. Its role as a chemically stable, versatile and multi-purpose fostered its massive use, which has finally translated into our current situation of planetary pollution. Moreover, when plastic degrades it breaks into smaller micro and nanoparticles, becoming present in the water we drink, the air we breathe and almost everything we touch. That is how nanoplastics penetrate the organism and produce side effects.

A revised study led by the Universitat Autónoma de Barcelona (UAB), the CREAF and the Centre for Environmental and Marine Studies (CESAM) at the University of Aviero, Portugal, and published in the journal Science Bulletin, verifies that the nanoplastics affect the composition and diversity of our intestinal microbiome and that this can cause damage to our health. This effect can be seen in both vertebrates and invertebrates, and has been proved in situations in which the exposure is widespread and prolonged. Additionally, with alteration of the gut microbiome come alterations in the immune, endocrine and and therefore, although not enough is known about the specific physiological mechanisms, the study alerts that stress to the gut microbiome could alter the health of humans.

The health effects of being exposed to nanoplastics was traditionally evaluated in aquatic animals such as molluscs, crustaceans and fish. Recent in vitro analyzes, using cell cultures of fish and mammals, has allowed scientists to analyze the changes in gene expression associated with the presence of nanoplastics from a toxicological viewpoint. The majority of neurological, endocrine and immunological tracts in these vertebrates are very similar to those of humans, and therefore authors warn that some of the effects observed in these models could also be applied to humans. Understanding and analyzing the process through which these plastic fragments penetrate the organism and harm it is fundamental, as is determining precisely the amount and typology of nanoplastics polluting the environment.

Preliminary results suggest anti-COVID19 nanobodies may be effective at preventing and diagnosing infections.

National Institutes of Health researchers have isolated a set of promising, tiny antibodies, or “nanobodies,” against SARS-CoV-2 that were produced by a llama named Cormac. Preliminary results published in Scientific Reports suggest that at least one of these nanobodies, called NIH-CoVnb-112, could prevent infections and detect virus particles by grabbing hold of SARS-CoV-2 spike proteins. In addition, the nanobody appeared to work equally well in either liquid or aerosol form, suggesting it could remain effective after inhalation. SARS-CoV-2 is the virus that causes COVID-19.

2020 GEO SDG Award for CirroLytix

MANILA, Philippines — A Filipino startup is recognized globally in developing a dengue hotspot prediction system using satellite and climate data in the 2020 Group on Earth Observations Sustainable Development Goals (GEO SDG) Awards for the Sectoral category, For-Profit. The GEO SDG Awards recognize the productivity, ingenuity, proficiency, novelty, and exemplary communications of results and experiences in the use of Earth observations to support sustainable development.

CirroLytix Research Services was formed to create social impact through big data. Through the application of machine learning, data engineering, remote sensing, and social listening, the Philippines-based data analytics firm hopes to help governments, researchers, non-government organizations (NGO), and social enterprises achieve positive change. The Advanced Early Dengue Prediction and Exploration Service (Project AEDES) is one of the CirroLytix’s flagship projects developed during the 2019 National Aeronautics and Space Administration’s (NASA) International Space Apps Challenge. It combines digital, climate, and remote sensing to nowcast dengue trends and detect mosquito habitats to help pre-empt cases of dengue. Project AEDES process leverages normalized difference vegetation index (NDVI), Fraction of absorbed photosynthetically active radiation (FAPAR), and normalized difference water index (NDWI) readings from Landsat and Sentinel-2 to estimate still water areas on the ground, which is correlated with dengue case counts from national health centers.

The Advanced Early Dengue Prediction and Exploration Service (Project AEDES) combines digital, climate, and remote sensing to nowcast dengue trends and detect mosquito habitats to help pre-empt cases of dengue.

Dominic Vincent “Doc” Ligot, co-founder and chief technology officer of CirroLytix, describes Project AEDES as an “early detection of panics from online searches, anticipating case counts from environment readings, but most importantly pinpointing hotspots from mosquito habitat detection.”

Rusted iron pipes can react with residual disinfectants in drinking water distribution systems to produce carcinogenic hexavalent chromium in drinking water, reports a study by engineers at UC Riverside.

Chromium is a metal that occurs naturally in the soil and groundwater. Trace amounts of trivalent eventually appear in the and food supply and are thought to have neutral effects on health. Chromium is often added to iron to make it more resistant to corrosion.

Certain can change chromium atoms into a hexavalent form that creates cancer-causing genetic mutations in cells. This carcinogenic form of chromium was at the heart of a lawsuit in California’s Central Valley by Erin Brockovich, which became the subject of an Oscar-winning movie.

ANCHORAGE, Alaska (Reuters) — A Fairbanks clinician suffered anaphylactic symptoms after being given the Pfizer Inc coronavirus vaccine, a hospital said on Friday, becoming the third Alaska health care worker to suffer an adverse reaction to the new drug. The clinician, whose name was not released, started showing symptoms about 10 minutes after being inoculated on Thursday, according to Foundation Health Partners, operator of the Fairbanks Memorial Hospital. The health care worker was treated in the hospital’s emergency room with epinephrine and released about six hours later, Foundation Health Partners said in a written statement. “Allergic reactions, though uncommon, can occur with injections of medications and vaccines,” Foundation Health Partners’ Chief Medical Officer Dr. Angelique Ramirez said in the statement.